Nivolumab vs Pembrolizumab in Patients With Platinum-Refractory Recurrent or Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
JAMA Netw Open 2021 May 03;4(5)e218065, R Pei, Y Shi, S Lv, T Dai, F Zhang, S Liu, B WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.